SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Simvastatin acid calcium hydrate

Cat. No.: HY-119695B

CAS No.: 530112-57-3

Molecular Formula: $C_{25}H_{40}O_6$

Target: HMG-CoA Reductase (HMGCR); Reactive Oxygen Species

Pathway: Metabolic Enzyme/Protease; Immunology/Inflammation; NF-κB

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Simvastatin acid (Tenivastatin) calcium hydrate is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid calcium hydrate reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid calcium hydrate can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene[1][2].
IC_{50} & Target	HMG-CoA reductase, Reactive oxygen species[1][2]
In Vitro	Simvastatin acid (0.1-20 μM; 24 h) significantly decreases ROS production between 8.9% and 43% in Indoxyl sulfate-treated hCM cells[2]. Simvastatin acid (0.1-20 μM; 24 h) alters the protein expression of OATP3A1 in hCMs and OATP3A1-expressing HEK293 cells[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[2]

Cell Line:	hCM and HEK293 (transfected with OATP3A1)
Concentration:	0.1, 1, 10 and 20 μM
Incubation Time:	24 h
Result:	Decreased 1.5% to 90% in OATP3A1 expression with a dose-dependent manner in both hCMs and OATP3A1-expressing cells.

REFERENCES

[1]. Eduardo Filipe Oliveira, et al. HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015). Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272.

[2]. Atilano-Roque A, et al. Characterization of simvastatin acid uptake by organic anion transporting polypeptide 3A1 (OATP3A1) and influence of drug-drug interaction. Toxicol In Vitro. 2017 Dec;45(Pt 1):158-165.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA